25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Orgenesis Inc
Buy, Hold or Sell?

Let's analyze Orgenesis together

I guess you are interested in Orgenesis Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Orgenesis Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Orgenesis Inc

I send you an email if I find something interesting about Orgenesis Inc.

1. Quick Overview

1.1. Quick analysis of Orgenesis (30 sec.)










1.2. What can you expect buying and holding a share of Orgenesis? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
5.4%

What is your share worth?

Current worth
$-0.41
Expected worth in 1 year
$-1.66
How sure are you?
32.4%

+ What do you gain per year?

Total Gains per Share
$-1.25
Return On Investment
-106.1%

For what price can you sell your share?

Current Price per Share
$1.18
Expected price per share
$1.03 - $3.9
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Orgenesis (5 min.)




Live pricePrice per Share (EOD)
$1.18
Intrinsic Value Per Share
$-9.85 - $90.10
Total Value Per Share
$-10.25 - $89.69

2.2. Growth of Orgenesis (5 min.)




Is Orgenesis growing?

Current yearPrevious yearGrowGrow %
How rich?-$15.7m$43.1m-$56.1m-432.8%

How much money is Orgenesis making?

Current yearPrevious yearGrowGrow %
Making money-$10.1m-$2.7m-$7.3m-72.6%
Net Profit Margin302.6%-36.7%--

How much money comes from the company's main activities?

2.3. Financial Health of Orgenesis (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#909 / 959

Most Revenue
#955 / 959

Most Profit
#566 / 959
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Orgenesis?

Welcome investor! Orgenesis's management wants to use your money to grow the business. In return you get a share of Orgenesis.

First you should know what it really means to hold a share of Orgenesis. And how you can make/lose money.

Speculation

The Price per Share of Orgenesis is $1.18. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Orgenesis.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Orgenesis, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.41. Based on the TTM, the Book Value Change Per Share is $-0.31 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.11 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Orgenesis.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.23-19.4%-0.29-24.9%-0.13-11.1%-0.11-9.2%-0.24-19.9%
Usd Book Value Change Per Share0.4235.9%-0.31-26.5%-0.11-9.3%-0.09-7.2%0.00-0.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.1%0.000.2%0.000.1%
Usd Total Gains Per Share0.4235.9%-0.31-26.5%-0.11-9.2%-0.08-7.0%0.00-0.1%
Usd Price Per Share0.60-0.64-1.49-2.86-2.69-
Price to Earnings Ratio-0.65--0.28--3.47--9.10--5.02-
Price-to-Total Gains Ratio1.42--1.36--8.53--9.14--2.28-
Price to Book Ratio-1.48--0.44-1.05-2.12-1.71-
Price-to-Total Gains Ratio1.42--1.36--8.53--9.14--2.28-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.18
Number of shares847
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.31-0.09
Usd Total Gains Per Share-0.31-0.08
Gains per Quarter (847 shares)-265.00-70.21
Gains per Year (847 shares)-1,059.99-280.86
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1060-10709-290-291
20-2120-213018-579-572
30-3180-319026-869-853
40-4240-425035-1159-1134
50-5300-531044-1448-1415
60-6360-637053-1738-1696
70-7420-743062-2028-1977
80-8480-849070-2317-2258
90-9540-955079-2607-2539
100-10600-1061088-2897-2820

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%1.010.00.09.1%2.015.00.011.8%6.031.00.016.2%6.049.00.010.9%
Book Value Change Per Share1.03.00.025.0%2.09.00.018.2%3.014.00.017.6%12.025.00.032.4%18.037.00.032.7%
Dividend per Share0.00.04.00.0%2.00.09.018.2%2.00.015.011.8%2.00.035.05.4%2.00.053.03.6%
Total Gains per Share1.03.00.025.0%2.09.00.018.2%3.014.00.017.6%12.025.00.032.4%18.037.00.032.7%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Orgenesis Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.424-0.313+174%-0.109+126%-0.085+120%-0.002+100%
Book Value Per Share---0.406-0.369-9%1.654-125%1.375-130%1.048-139%
Current Ratio--0.0740.251-70%2.031-96%2.082-96%1.293-94%
Debt To Asset Ratio--1.5161.644-8%0.462+228%0.736+106%0.941+61%
Debt To Equity Ratio---0.664-100%1.250-100%1.975-100%1.738-100%
Dividend Per Share----0%0.001-100%0.003-100%0.001-100%
Eps---0.229-0.294+28%-0.131-43%-0.109-52%-0.235+3%
Free Cash Flow Per Share---0.152-0.090-41%-0.371+144%-0.427+181%-0.307+102%
Free Cash Flow To Equity Per Share--0.016-0.040+361%-0.186+1300%-0.319+2153%-0.101+752%
Gross Profit Margin--1.0251.087-6%2.101-51%1.289-20%1.133-10%
Intrinsic Value_10Y_max--90.096--------
Intrinsic Value_10Y_min---9.849--------
Intrinsic Value_1Y_max--0.391--------
Intrinsic Value_1Y_min---1.195--------
Intrinsic Value_3Y_max--7.756--------
Intrinsic Value_3Y_min---3.433--------
Intrinsic Value_5Y_max--23.059--------
Intrinsic Value_5Y_min---5.478--------
Market Cap5629520.400-314%23316436.20021130808.402+10%39069113.330-40%65327987.713-64%47147891.827-51%
Net Profit Margin---36.1953.026-1296%-0.367-99%-1.705-95%-1.391-96%
Operating Margin---16.537-23.834+44%-0.178-99%-8.391-49%-4.589-72%
Operating Ratio--17.53724.763-29%1.222+1335%9.276+89%5.385+226%
Pb Ratio-2.904-97%-1.476-0.441-70%1.050-241%2.120-170%1.715-186%
Pe Ratio-1.288-97%-0.655-0.278-58%-3.468+430%-9.102+1290%-5.020+667%
Price Per Share1.180+49%0.6000.636-6%1.485-60%2.856-79%2.688-78%
Price To Free Cash Flow Ratio-1.940-97%-0.987-3.156+220%-1.100+12%-2.279+131%-2.334+137%
Price To Total Gains Ratio2.783+49%1.415-1.356+196%-8.528+703%-9.141+746%-2.276+261%
Quick Ratio--0.0440.210-79%1.952-98%1.987-98%1.183-96%
Return On Assets---0.291-0.673+131%-0.039-87%-0.246-15%-0.214-27%
Return On Equity---0.255-100%-0.1050%-0.1630%-0.1840%
Total Gains Per Share--0.424-0.313+174%-0.109+126%-0.083+120%-0.001+100%
Usd Book Value---15792000.000-12981750.000-18%43199250.000-137%31247352.941-151%20073319.865-179%
Usd Book Value Change Per Share--0.424-0.313+174%-0.109+126%-0.085+120%-0.002+100%
Usd Book Value Per Share---0.406-0.369-9%1.654-125%1.375-130%1.048-139%
Usd Dividend Per Share----0%0.001-100%0.003-100%0.001-100%
Usd Eps---0.229-0.294+28%-0.131-43%-0.109-52%-0.235+3%
Usd Free Cash Flow---5908000.000-3147750.000-47%-9683000.000+64%-10023529.412+70%-5860133.243-1%
Usd Free Cash Flow Per Share---0.152-0.090-41%-0.371+144%-0.427+181%-0.307+102%
Usd Free Cash Flow To Equity Per Share--0.016-0.040+361%-0.186+1300%-0.319+2153%-0.101+752%
Usd Market Cap5629520.400-314%23316436.20021130808.402+10%39069113.330-40%65327987.713-64%47147891.827-51%
Usd Price Per Share1.180+49%0.6000.636-6%1.485-60%2.856-79%2.688-78%
Usd Profit---8904000.000-10102000.000+13%-2767000.000-69%-9403294.118+6%-5964291.378-33%
Usd Revenue--246000.000-3275500.000+1432%8907750.000-97%4695000.000-95%3594270.270-93%
Usd Total Gains Per Share--0.424-0.313+174%-0.109+126%-0.083+120%-0.001+100%
 EOD+5 -3MRQTTM+21 -13YOY+13 -225Y+14 -2110Y+14 -21

3.3 Fundamental Score

Let's check the fundamental score of Orgenesis Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.288
Price to Book Ratio (EOD)Between0-1-2.904
Net Profit Margin (MRQ)Greater than0-36.195
Operating Margin (MRQ)Greater than0-16.537
Quick Ratio (MRQ)Greater than10.044
Current Ratio (MRQ)Greater than10.074
Debt to Asset Ratio (MRQ)Less than11.516
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.291
Total1/10 (10.0%)

3.4 Technical Score

Let's check the technical score of Orgenesis Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5026.037
Ma 20Greater thanMa 501.788
Ma 50Greater thanMa 1003.846
Ma 100Greater thanMa 2005.415
OpenGreater thanClose1.180
Total0/5 (0.0%)

4. In-depth Analysis

4.1 About Orgenesis Inc

Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.

Fundamental data was last updated by Penke on 2024-10-24 22:42:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Orgenesis earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Orgenesis to the Biotechnology industry mean.
  • A Net Profit Margin of -3,619.5% means that $-36.20 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Orgenesis Inc:

  • The MRQ is -3,619.5%. The company is making a huge loss. -2
  • The TTM is 302.6%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ-3,619.5%TTM302.6%-3,922.2%
TTM302.6%YOY-36.7%+339.3%
TTM302.6%5Y-170.5%+473.2%
5Y-170.5%10Y-139.1%-31.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3,619.5%-135.3%-3,484.2%
TTM302.6%-204.4%+507.0%
YOY-36.7%-207.5%+170.8%
5Y-170.5%-353.2%+182.7%
10Y-139.1%-464.5%+325.4%
4.3.1.2. Return on Assets

Shows how efficient Orgenesis is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Orgenesis to the Biotechnology industry mean.
  • -29.1% Return on Assets means that Orgenesis generated $-0.29 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Orgenesis Inc:

  • The MRQ is -29.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -67.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-29.1%TTM-67.3%+38.2%
TTM-67.3%YOY-3.9%-63.4%
TTM-67.3%5Y-24.6%-42.6%
5Y-24.6%10Y-21.4%-3.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-29.1%-10.7%-18.4%
TTM-67.3%-11.8%-55.5%
YOY-3.9%-11.0%+7.1%
5Y-24.6%-12.6%-12.0%
10Y-21.4%-14.3%-7.1%
4.3.1.3. Return on Equity

Shows how efficient Orgenesis is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Orgenesis to the Biotechnology industry mean.
  • 0.0% Return on Equity means Orgenesis generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Orgenesis Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM25.5%-25.5%
TTM25.5%YOY-10.5%+36.0%
TTM25.5%5Y-16.3%+41.8%
5Y-16.3%10Y-18.4%+2.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--13.5%+13.5%
TTM25.5%-15.9%+41.4%
YOY-10.5%-13.5%+3.0%
5Y-16.3%-18.5%+2.2%
10Y-18.4%-19.0%+0.6%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Orgenesis Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Orgenesis is operating .

  • Measures how much profit Orgenesis makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Orgenesis to the Biotechnology industry mean.
  • An Operating Margin of -1,653.7% means the company generated $-16.54  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Orgenesis Inc:

  • The MRQ is -1,653.7%. The company is operating very inefficient. -2
  • The TTM is -2,383.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-1,653.7%TTM-2,383.4%+729.8%
TTM-2,383.4%YOY-17.8%-2,365.7%
TTM-2,383.4%5Y-839.1%-1,544.3%
5Y-839.1%10Y-458.9%-380.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,653.7%-277.1%-1,376.6%
TTM-2,383.4%-312.4%-2,071.0%
YOY-17.8%-223.5%+205.7%
5Y-839.1%-384.9%-454.2%
10Y-458.9%-494.6%+35.7%
4.3.2.2. Operating Ratio

Measures how efficient Orgenesis is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 17.54 means that the operating costs are $17.54 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Orgenesis Inc:

  • The MRQ is 17.537. The company is inefficient in keeping operating costs low. -1
  • The TTM is 24.763. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ17.537TTM24.763-7.226
TTM24.763YOY1.222+23.541
TTM24.7635Y9.276+15.487
5Y9.27610Y5.385+3.890
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ17.5372.842+14.695
TTM24.7633.179+21.584
YOY1.2223.301-2.079
5Y9.2764.794+4.482
10Y5.3856.520-1.135
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Orgenesis Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Orgenesis is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.07 means the company has $0.07 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Orgenesis Inc:

  • The MRQ is 0.074. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.251. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.074TTM0.251-0.177
TTM0.251YOY2.031-1.780
TTM0.2515Y2.082-1.832
5Y2.08210Y1.293+0.789
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0743.783-3.709
TTM0.2513.923-3.672
YOY2.0314.715-2.684
5Y2.0825.960-3.878
10Y1.2936.285-4.992
4.4.3.2. Quick Ratio

Measures if Orgenesis is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Orgenesis to the Biotechnology industry mean.
  • A Quick Ratio of 0.04 means the company can pay off $0.04 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Orgenesis Inc:

  • The MRQ is 0.044. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.210. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.044TTM0.210-0.166
TTM0.210YOY1.952-1.742
TTM0.2105Y1.987-1.777
5Y1.98710Y1.183+0.803
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0443.349-3.305
TTM0.2103.522-3.312
YOY1.9524.691-2.739
5Y1.9875.927-3.940
10Y1.1836.469-5.286
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Orgenesis Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Orgenesis assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Orgenesis to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.52 means that Orgenesis assets are financed with 151.6% credit (debt) and the remaining percentage (100% - 151.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Orgenesis Inc:

  • The MRQ is 1.516. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.644. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ1.516TTM1.644-0.127
TTM1.644YOY0.462+1.182
TTM1.6445Y0.736+0.908
5Y0.73610Y0.941-0.205
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5160.338+1.178
TTM1.6440.347+1.297
YOY0.4620.309+0.153
5Y0.7360.365+0.371
10Y0.9410.380+0.561
4.5.4.2. Debt to Equity Ratio

Measures if Orgenesis is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Orgenesis to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Orgenesis Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.664-0.664
TTM0.664YOY1.250-0.586
TTM0.6645Y1.975-1.312
5Y1.97510Y1.738+0.237
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.389-0.389
TTM0.6640.437+0.227
YOY1.2500.375+0.875
5Y1.9750.450+1.525
10Y1.7380.488+1.250
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Orgenesis generates.

  • Above 15 is considered overpriced but always compare Orgenesis to the Biotechnology industry mean.
  • A PE ratio of -0.65 means the investor is paying $-0.65 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Orgenesis Inc:

  • The EOD is -1.288. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.655. Based on the earnings, the company is expensive. -2
  • The TTM is -0.278. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.288MRQ-0.655-0.633
MRQ-0.655TTM-0.278-0.377
TTM-0.278YOY-3.468+3.191
TTM-0.2785Y-9.102+8.824
5Y-9.10210Y-5.020-4.082
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.288-2.431+1.143
MRQ-0.655-2.454+1.799
TTM-0.278-2.994+2.716
YOY-3.468-3.435-0.033
5Y-9.102-6.005-3.097
10Y-5.020-6.275+1.255
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Orgenesis Inc:

  • The EOD is -1.940. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.987. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.156. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.940MRQ-0.987-0.954
MRQ-0.987TTM-3.156+2.169
TTM-3.156YOY-1.100-2.055
TTM-3.1565Y-2.279-0.877
5Y-2.27910Y-2.334+0.055
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.940-3.231+1.291
MRQ-0.987-3.234+2.247
TTM-3.156-3.528+0.372
YOY-1.100-4.567+3.467
5Y-2.279-8.099+5.820
10Y-2.334-8.945+6.611
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Orgenesis is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -1.48 means the investor is paying $-1.48 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Orgenesis Inc:

  • The EOD is -2.904. Based on the equity, the company is expensive. -2
  • The MRQ is -1.476. Based on the equity, the company is expensive. -2
  • The TTM is -0.441. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.904MRQ-1.476-1.427
MRQ-1.476TTM-0.441-1.036
TTM-0.441YOY1.050-1.491
TTM-0.4415Y2.120-2.561
5Y2.12010Y1.715+0.406
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.9041.938-4.842
MRQ-1.4761.983-3.459
TTM-0.4412.193-2.634
YOY1.0502.392-1.342
5Y2.1203.608-1.488
10Y1.7154.220-2.505
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Orgenesis Inc.

4.8.1. Institutions holding Orgenesis Inc

Institutions are holding 4.546% of the shares of Orgenesis Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-06-30Vanguard Group Inc1.9080910250-14863-1.6066
2024-06-30Geode Capital Management, LLC0.59340283077-4878-1.694
2024-06-30BlackRock Inc0.1675079889-45336-36.2036
2024-06-30State Street Corp0.16530788781121916.5817
2024-06-30Northern Trust Corp0.0849040512-161-0.3958
2024-06-30Bank Hapoalim BM0.06720.00273205200
2024-06-30Renaissance Technologies Corp0.0618029499-5100-14.7403
2024-06-30CAMBRIDGE Invest RESEARCH ADVISORS, INC.0.038401833000
2024-06-30XTX Topco Ltd0.03410.000816280162800
2024-06-30Virtu Financial LLC0.02540.000512112121120
2024-06-30UBS Group AG0.01310627362730
2024-06-30Tower Research Capital LLC0.001306316310
2024-06-30Royal Bank of Canada0.0010465361347.1154
2024-06-30Bank of America Corp0.0010464264132
2024-06-30JPMorgan Chase & Co0.0003015942.5806
2024-06-30BNP Paribas Arbitrage, SA0.000207500
2024-06-30Qube Research & Technologies00200
2024-06-30Wells Fargo & Co000-242-100
2024-06-30Jane Street Group LLC000-11998-100
2024-03-31Prudential Financial Inc000-11000-100
Total 3.16290.0041508948-46434-3.1%

4.9.2. Funds holding Orgenesis Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-08-31Vanguard Total Stock Mkt Idx Inv1.1878056668800
2024-08-31Vanguard Institutional Extnd Mkt Idx Tr0.63080.000230095700
2024-08-31Fidelity Extended Market Index0.36850.0003175822-2829-1.5835
2024-08-31Fidelity Total Market Index0.085604082100
2024-08-31Vanguard Balanced Index Inv0.067603226100
2024-08-31Fidelity Series Total Market Index0.059602841100
2023-12-31SSgA U.S. Extended Market Index Class I0.0440.00042100000
2024-06-30Northern Trust Extended Eq Market Idx0.0430.00022052700
2024-08-31Spartan Total Market Index Pool E0.0332015827632966.6351
2024-08-31Fidelity Nasdaq Composite Index0.03130.00011493100
2024-03-31Vanguard Instl Ttl Stck Mkt Idx Tr0.031201486300
2024-08-31Spartan Extended Market Index Pool E0.02820.000213471282926.5833
2024-09-30BlackRock Extended Equity Market K0.10890.00025195-3-0.0577
2024-09-30NT Ext Equity Mkt Idx Fd - L0.0430.0001205300
2024-06-30Northern Trust Wilshire 50000.00410196800
2024-09-30NT Ext Equity Mkt Idx Fd - NL0.03780.0001180200
2024-09-30NT Ext Equity Mkt Idx Fd - DC - NL - T20.03040.0001145240.2762
2024-09-30Vanguard U.S. Eq Idx £ Acc0.02170103400
2024-09-30Extended Equity Market Fund M0.01380.0002659-2-0.3026
2023-12-31NT US Market Cap Idx Fd - L0.00090417-2105-83.4655
Total 2.87140.00211260159+4223+0.3%

5.3. Insider Transactions

Insiders are holding 21.166% of the shares of Orgenesis Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-02-01Jacob SafierBUY101000.33
2024-01-30Jacob SafierBUY250000.33
2024-01-25Jacob SafierBUY250000.32
2024-01-22Jacob SafierBUY100000.29
2024-01-18Jacob SafierBUY100000.33
2024-01-10Jacob SafierBUY100000.37
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets30,577
Total Liabilities46,369
Total Stockholder Equity-15,498
 As reported
Total Liabilities 46,369
Total Stockholder Equity+ -15,498
Total Assets = 30,577

Assets

Total Assets30,577
Total Current Assets2,348
Long-term Assets28,229
Total Current Assets
Cash And Cash Equivalents 1,156
Net Receivables 240
Other Current Assets 952
Total Current Assets  (as reported)2,348
Total Current Assets  (calculated)2,348
+/-0
Long-term Assets
Property Plant Equipment 17,706
Goodwill 1,211
Long Term Investments 8
Intangible Assets 8,724
Long-term Assets Other 331
Long-term Assets  (as reported)28,229
Long-term Assets  (calculated)27,980
+/- 249

Liabilities & Shareholders' Equity

Total Current Liabilities31,700
Long-term Liabilities14,669
Total Stockholder Equity-15,498
Total Current Liabilities
Short-term Debt 3,644
Short Long Term Debt 3,117
Accounts payable 13,413
Other Current Liabilities 5,190
Total Current Liabilities  (as reported)31,700
Total Current Liabilities  (calculated)25,364
+/- 6,336
Long-term Liabilities
Long term Debt 8,058
Capital Lease Obligations 1,846
Long-term Liabilities Other 5,196
Long-term Liabilities  (as reported)14,669
Long-term Liabilities  (calculated)15,100
+/- 431
Total Stockholder Equity
Common Stock5
Retained Earnings -195,291
Accumulated Other Comprehensive Income 302
Other Stockholders Equity 179,486
Total Stockholder Equity (as reported)-15,498
Total Stockholder Equity (calculated)-15,498
+/-0
Other
Capital Stock5
Cash and Short Term Investments 1,156
Common Stock Shares Outstanding 38,861
Current Deferred Revenue9,453
Liabilities and Stockholders Equity 30,577
Net Debt 11,865
Net Invested Capital -4,323
Net Working Capital -29,352
Property Plant and Equipment Gross 17,706
Short Long Term Debt Total 13,021



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-05-312012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-11-302009-09-302009-03-312008-12-31
> Total Assets 
0
0
34
32
32
27
23
20
2
7
6
5
2
354
182
350
48
98
1,133
114
600
293
154
1,660
2,249
1,227
34,584
35,551
38,748
36,200
36,746
36,555
33,487
36,272
36,267
37,422
39,872
42,411
47,033
69,296
75,447
84,770
84,555
79,599
92,495
127,209
119,196
110,752
77,684
82,110
75,558
65,204
59,841
58,538
62,799
70,690
90,928
93,267
54,767
45,299
14,552
30,920
30,577
30,57730,92014,55245,29954,76793,26790,92870,69062,79958,53859,84165,20475,55882,11077,684110,752119,196127,20992,49579,59984,55584,77075,44769,29647,03342,41139,87237,42236,26736,27233,48736,55536,74636,20038,74835,55134,5841,2272,2491,6601542936001141,13398483501823542567220232732323400
   > Total Current Assets 
0
0
19
17
17
12
8
5
2
7
6
5
2
354
175
340
39
83
1,118
98
583
277
135
1,640
2,230
1,202
2,511
2,999
8,206
5,055
5,147
5,292
4,205
7,428
6,110
5,674
7,295
8,569
13,738
24,654
30,297
23,932
27,092
20,773
25,979
112,930
104,312
94,983
50,077
54,713
47,848
36,341
25,758
24,010
25,458
31,856
46,318
49,450
9,295
8,776
4,076
1,956
2,348
2,3481,9564,0768,7769,29549,45046,31831,85625,45824,01025,75836,34147,84854,71350,07794,983104,312112,93025,97920,77327,09223,93230,29724,65413,7388,5697,2955,6746,1107,4284,2055,2925,1475,0558,2062,9992,5111,2022,2301,640135277583981,118833934017535425672581217171900
       Cash And Cash Equivalents 
0
0
18
16
16
12
7
4
1
7
6
5
1
354
127
314
0
50
1,069
51
516
237
12
1,533
1,314
520
185
264
4,168
933
474
270
891
3,872
658
762
3,519
4,225
4,502
16,741
16,064
14,361
16,111
10,054
11,388
107,069
97,487
88,758
44,923
41,841
28,431
14,917
5,473
1,123
2,303
3,015
5,311
2,674
180
55
837
565
1,156
1,156565837551802,6745,3113,0152,3031,1235,47314,91728,43141,84144,92388,75897,487107,06911,38810,05416,11114,36116,06416,7414,5024,2253,5197626583,8728912704749334,1682641855201,3141,53312237516511,06950031412735415671471216161800
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10
10
10
10
10
10
10
10
0
5
5
5
0
0
0
0
0
79
0
0
0
0
383
396
0
0
0
0
0
0
0
0
0
0
0
0
152
0
0
0
0
0
0
0
0
0
0
000000000015200000000000039638300007900000555010101010101010100000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
15
23
39
37
37
29
112,230
0
811
677
1,439
2,071
2,619
2,731
3,143
3,260
2,135
1,546
3,095
2,279
2,210
2,554
3,424
4,421
11,192
6,192
7,138
7,293
10,668
3,071
4,156
4,282
3,254
11,522
17,364
19,137
18,478
20,846
21,798
26,395
39,829
45,591
8,034
7,953
2,563
245
240
2402452,5637,9538,03445,59139,82926,39521,79820,84618,47819,13717,36411,5223,2544,2824,1563,07110,6687,2937,1386,19211,1924,4213,4242,5542,2102,2793,0951,5462,1353,2603,1432,7312,6192,0711,4396778110112,2302937373923150000000000000000
       Other Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
1
0
47
27
10
23
39
37
57
29
112
96
105
682
628
399
1,118
973
1,117
1,371
779
1,317
1,453
1,668
841
909
792
1,833
1,305
1,387
1,622
1,567
1,880
2,664
2,493
1,790
1,715
1,150
1,880
2,154
4,770
5,699
4,262
2,351
4,704
1,057
1,047
734
642
1,112
952
9521,1126427341,0471,0574,7042,3514,2625,6994,7702,1541,8801,1501,7151,7902,4932,6641,8801,5671,6221,3871,3051,8337929098411,6681,4531,3177791,3711,1179731,11839962868210596112295737392310274701000000000000
   > Long-term Assets 
0
0
15
0
15
15
15
15
0
0
0
0
0
7
7
9
10
15
15
16
17
17
20
21
19
25
32,073
32,551
30,542
31,145
31,599
31,263
29,282
28,844
30,157
31,748
32,577
33,842
33,295
44,642
45,150
60,838
57,463
58,826
66,516
14,279
14,884
15,769
27,607
27,397
27,710
28,863
34,083
34,528
37,341
38,834
44,610
43,817
45,472
36,523
10,476
28,964
28,229
28,22928,96410,47636,52345,47243,81744,61038,83437,34134,52834,08328,86327,71027,39727,60715,76914,88414,27966,51658,82657,46360,83845,15044,64233,29533,84232,57731,74830,15728,84429,28231,26331,59931,14530,54232,55132,07325192120171716151510977000001515151501500
       Property Plant Equipment 
0
0
15
0
0
0
0
0
0
0
0
0
0
7
7
9
8
13
13
13
14
12
15
16
13
18
4,008
4,320
4,296
4,564
4,787
4,915
4,573
4,584
4,807
5,025
5,104
5,617
7,517
11,056
11,901
27,137
24,283
27,337
34,039
3,088
2,900
3,514
4,547
4,810
5,353
6,828
11,286
11,990
15,145
17,566
25,138
24,712
1,743
1,934
1,826
18,208
17,706
17,70618,2081,8261,9341,74324,71225,13817,56615,14511,99011,2866,8285,3534,8104,5473,5142,9003,08834,03927,33724,28327,13711,90111,0567,5175,6175,1045,0254,8074,5844,5734,9154,7874,5644,2964,3204,008181316151214131313897700000000001500
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,887
10,103
9,535
9,812
10,059
10,049
9,584
9,557
10,048
10,683
10,684
11,013
10,549
15,632
15,165
15,002
15,066
14,489
14,941
4,592
4,658
4,763
8,745
8,602
8,599
8,414
8,403
8,329
8,174
7,764
8,187
8,069
3,703
3,703
1,211
1,211
1,211
1,2111,2111,2113,7033,7038,0698,1877,7648,1748,3298,4038,4148,5998,6028,7454,7634,6584,59214,94114,48915,06615,00215,16515,63210,54911,01310,68410,68310,0489,5579,58410,04910,0599,8129,53510,1039,88700000000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
252
475
1,321
1,712
1,136
91
85
0
0
2,623
3,161
0
3,211
175
160
0
160
397
1,574
0
1,750
1,739
136
136
31,484
22,509
8
8
8
88822,50931,4841361361,7391,75001,57439716001601753,21103,1612,6230085911,1361,7121,3214752520000000000000000000000000000000000
       Intangible Assets 
0
0
0
15
15
15
15
15
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
18,138
18,087
16,653
16,707
16,683
16,220
15,050
14,626
14,969
15,480
15,051
15,076
14,011
17,576
16,700
15,823
15,396
14,256
14,206
3,074
3,044
3,041
13,023
12,675
12,435
12,064
11,821
11,539
11,207
10,720
9,694
9,430
7,681
7,528
7,375
8,950
8,724
8,7248,9507,3757,5287,6819,4309,69410,72011,20711,53911,82112,06412,43512,67513,0233,0413,0443,07414,20614,25615,39615,82316,70017,57614,01115,07615,05115,48014,96914,62615,05016,22016,68316,70716,65318,08718,1380000000000000000001515151515000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
2
3
3
0
4
5
5
6
6
28,065
28,231
26,246
26,581
26,812
26,348
24,709
24,260
25,350
26,723
27,473
424
82
287
1,299
843
2,718
3,330
3,525
0
4,282
1,398
2,766
0
1,163
1,160
1,096
0
1,065
1,045
0
0
861
0
0
0
0
0000861001,0451,06501,0961,1601,16302,7661,3984,28203,5253,3302,7188431,2992878242427,47326,72325,35024,26024,70926,34826,81226,58126,24628,23128,06566554033211000000000000000
> Total Liabilities 
0
0
3
6
6
4
5
7
12
23
24
26
85
160
243
193
329
358
2,101
2,149
1,906
1,993
1,741
5,758
5,228
4,850
39,632
41,510
45,188
19,518
21,219
22,720
22,909
30,557
26,369
26,171
25,749
22,933
21,232
39,332
46,798
63,369
67,801
68,502
86,417
37,546
30,807
23,944
24,956
27,358
24,058
21,943
21,210
23,681
30,956
40,440
31,654
33,959
30,802
32,902
35,535
58,469
46,369
46,36958,46935,53532,90230,80233,95931,65440,44030,95623,68121,21021,94324,05827,35824,95623,94430,80737,54686,41768,50267,80163,36946,79839,33221,23222,93325,74926,17126,36930,55722,90922,72021,21919,51845,18841,51039,6324,8505,2285,7581,7411,9931,9062,1492,101358329193243160852624231275466300
   > Total Current Liabilities 
0
0
3
6
6
4
5
7
12
23
24
26
85
160
243
192
327
356
696
986
740
1,249
1,179
4,318
4,663
4,438
8,218
10,393
16,476
12,412
14,408
14,924
14,576
18,123
16,147
17,571
16,914
16,164
12,972
14,953
17,145
21,752
23,064
24,363
31,579
25,910
19,758
12,355
16,285
18,930
18,156
13,566
15,365
15,253
16,245
34,168
15,910
13,938
12,711
14,302
16,407
29,031
31,700
31,70029,03116,40714,30212,71113,93815,91034,16816,24515,25315,36513,56618,15618,93016,28512,35519,75825,91031,57924,36323,06421,75217,14514,95312,97216,16416,91417,57116,14718,12314,57614,92414,40812,41216,47610,3938,2184,4384,6634,3181,1791,249740986696356327192243160852624231275466300
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
237
264
258
371
0
2,629
2,451
2,523
3,676
4,805
7,739
5,011
5,307
5,501
5,491
5,467
2,605
3,165
3,158
1,958
933
1,019
1,025
2,536
2,871
2,890
3,192
710
650
708
4,623
4,819
7,217
4,876
6,384
3,826
5,984
22,991
5,106
3,051
2,616
3,207
3,554
3,511
3,644
3,6443,5113,5543,2072,6163,0515,10622,9915,9843,8266,3844,8767,2174,8194,6237086507103,1922,8902,8712,5361,0251,0199331,9583,1583,1652,6055,4675,4915,5015,3075,0117,7394,8053,6762,5232,4512,6290371258264237000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,451
0
0
0
2,854
0
0
0
4,822
5,469
7,661
8,006
3,158
1,958
933
1,019
746
1,013
1,022
1,179
383
0
393
4,119
4,327
0
6,719
4,382
3,357
0
5,568
22,488
2,314
2,314
2,344
2,970
2,970
2,970
3,117
3,1172,9702,9702,9702,3442,3142,31422,4885,56803,3574,3826,71904,3274,11939303831,1791,0221,0137461,0199331,9583,1588,0067,6615,4694,8220002,8540002,451000000000000000000000000
       Accounts payable 
0
0
3
0
2
3
4
7
7
22
7
7
45
17
43
57
136
135
59
139
151
171
191
237
1,084
524
2,392
2,788
3,475
2,865
4,209
4,288
4,554
4,056
3,541
3,689
3,914
3,838
2,388
2,962
3,804
5,522
6,786
7,693
11,305
1,397
1,625
3,587
8,649
10,294
5,212
3,056
5,238
6,933
5,203
4,538
4,429
4,387
3,826
4,983
6,584
16,404
13,413
13,41316,4046,5844,9833,8264,3874,4294,5385,2036,9335,2383,0565,21210,2948,6493,5871,6251,39711,3057,6936,7865,5223,8042,9622,3883,8383,9143,6893,5414,0564,5544,2884,2092,8653,4752,7882,3925241,08423719117115113959135136574317457722774320300
       Other Current Liabilities 
0
0
0
0
5
1
1
1
5
1
18
19
41
143
200
136
191
221
400
584
121
708
988
1,342
1,043
838
1,497
1,688
3,739
2,874
3,139
3,189
3,015
3,674
3,636
3,795
4,512
3,795
3,640
3,490
5,275
4,651
4,848
5,337
5,706
22,985
16,945
7,536
2,262
2,632
4,531
4,467
2,446
3,208
3,844
5,177
4,727
4,804
4,788
4,736
4,089
6,421
5,190
5,1906,4214,0894,7364,7884,8044,7275,1773,8443,2082,4464,4674,5312,6322,2627,53616,94522,9855,7065,3374,8484,6515,2753,4903,6403,7954,5123,7953,6363,6743,0153,1893,1392,8743,7391,6881,4978381,0431,3429887081215844002211911362001434119181511150000
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
2
2
1,405
1,162
1,165
743
562
1,440
565
412
31,413
31,117
28,712
7,106
6,811
7,796
8,333
12,434
10,222
8,600
8,835
6,769
8,260
24,379
29,653
41,617
44,737
44,139
54,838
11,636
11,049
11,589
8,671
8,428
5,902
8,377
5,845
8,428
14,711
6,272
15,744
20,021
18,091
18,600
19,128
29,438
14,669
14,66929,43819,12818,60018,09120,02115,7446,27214,7118,4285,8458,3775,9028,4288,67111,58911,04911,63654,83844,13944,73741,61729,65324,3798,2606,7698,8358,60010,22212,4348,3337,7966,8117,10628,71231,11731,4134125651,4405627431,1651,1621,405221000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,700
3,393
10,343
14,061
10,853
0
10,262
10,503
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000010,50310,262010,85314,06110,3433,3932,7000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
2
2
1,405
1,162
0
743
561
1,440
565
412
31
10
1,387
1,455
1,735
2,224
2,121
5,068
3,139
1,151
6
318
236
3,933
2,800
2,175
2,405
2,298
393
0
348
387
394
0
402
388
387
0
387
564
578
0
60
0
0
0
0
00006005785643870387388402039438734803932,2982,4052,1752,8003,93323631861,1513,1395,0682,1212,2241,7351,4551,38710314125651,44056174301,1621,405221000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,327
0
0
0
1,862
2,373
2,027
2,608
690
312
0
0
0
0
0
1,926
37
0
20
3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000003200371,926000003126902,6082,0272,3731,8620003,3270000000000000000000000000000
> Total Stockholder Equity
0
0
31
0
26
23
18
13
-10
-16
-18
-21
-83
194
-62
156
-281
-260
-968
-2,034
-1,306
-1,699
-1,586
-4,098
-2,979
-3,623
-5,048
-5,960
-6,440
16,682
15,527
13,835
10,578
5,715
9,898
11,251
14,123
19,478
25,801
29,625
28,350
20,762
16,115
10,466
5,477
89,514
88,234
86,660
52,579
54,549
51,363
43,116
38,488
34,702
31,753
30,212
27,561
27,667
23,965
12,397
-20,983
-27,717
-15,498
-15,498-27,717-20,98312,39723,96527,66727,56130,21231,75334,70238,48843,11651,36354,54952,57986,66088,23489,5145,47710,46616,11520,76228,35029,62525,80119,47814,12311,2519,8985,71510,57813,83515,52716,682-6,440-5,960-5,048-3,623-2,979-4,098-1,586-1,699-1,306-2,034-968-260-281156-62194-83-21-18-16-101318232603100
   Common Stock
0
0
2
0
2
0
2
0
2
2
2
8
8
5
5
5
5
5
5
5
5
5
5
6
6
6
6
6
6
11
11
11
12
12
12
12
1
5,998
1
1
1
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
3
3
3
4
5
54333333333333322222221115,99811212121211111166666655555555558822202020200
   Retained Earnings Total Equity000000000000000-36,707-34,2800-13,874-89,4290000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-5
0
0
0
0
-18
-120
-578
-134
-1,286
-782
-202
-239
-1,205
-1,300
-216
1,214
1,425
2,000
1,076
660
425
185
373
-751
213
-237
10
292
748
471
519
290
207
56
-270
-826
-270
-311
62
71
65
281
302
302281657162-311-270-826-2705620729051947174829210-237213-7513731854256601,0762,0001,4251,214-216-1,300-1,205-239-202-782-1,286-134-578-120-180000-50000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
90,335
94,049
94,415
94,691
103,623
0
122,502
123,073
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000123,073122,5020103,62394,69194,41594,04990,3350000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
53
0
53
55
53
55
53
53
53
47
47
1,181
1,800
3,893
4,850
6,201
7,049
8,640
7,648
9,680
11,588
12,569
13,143
13,281
13,120
14,156
13,605
37,019
39,200
39,889
41,400
43,762
48,682
50,732
55,759
61,211
76,907
80,549
93,186
94,234
94,788
94,688
101,518
103,386
122,502
123,073
140,147
142,189
142,038
144,179
144,793
145,024
147,828
148,199
149,089
153,425
153,477
154,553
155,571
158,384
179,486
179,486158,384155,571154,553153,477153,425149,089148,199147,828145,024144,793144,179142,038142,189140,147123,073122,502103,386101,51894,68894,78894,23493,18680,54976,90761,21155,75950,73248,68243,76241,40039,88939,20037,01913,60514,15613,12013,28113,14312,56911,5889,6807,6488,6407,0496,2014,8503,8931,8001,18147475353535553555305300



5.3. Balance Sheets

Currency in USD. All numbers in thousands.